SITC strategic vision: prevention, premalignant immunity, host and environmental factors
Cancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immuni...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/3/e010419.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717165377191936 |
|---|---|
| author | Raymond H Kim Christian M Capitini Mary L Disis Claire Vanpouille-Box Laszlo Radvanyi Jennifer Wargo Sasha E Stanton Jennifer McQuade Saman Maleki Vareki Tullia C Bruno Kristin G Anderson Adnan Rajeh Lauren K Hughes Kelly J Baines Megan M Y Hong Phillip Awadalla |
| author_facet | Raymond H Kim Christian M Capitini Mary L Disis Claire Vanpouille-Box Laszlo Radvanyi Jennifer Wargo Sasha E Stanton Jennifer McQuade Saman Maleki Vareki Tullia C Bruno Kristin G Anderson Adnan Rajeh Lauren K Hughes Kelly J Baines Megan M Y Hong Phillip Awadalla |
| author_sort | Raymond H Kim |
| collection | DOAJ |
| description | Cancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immunity and immune changes seen in lesions that develop into invasive cancer versus those that regress offers an exciting opportunity to leverage the immune system for immune prevention and immune interception of premalignancy. Understanding the immune environment of premalignant lesions and how chronic inflammation plays a central role in the evolution of premalignancy is essential for developing effective immunoprevention and immune interceptions. Factors such as host genomics and environmental factors that affect premalignant immunity and the outcome of advanced cancers are equally important in determining the response to immunotherapy. The broad use of antibiotics and factors such as obesity can disrupt a healthy gut microbiome and drive chronic inflammation that suppresses preventive immunity or the antitumor immune response required for successful immunotherapy in advanced cancers. Modifiable lifestyle factors such as diet, obesity, smoking, and stress should be considered in designing immune prevention and interception studies, as well as for patients who receive immunotherapy for advanced cancer treatment. Other factors, such as the overall immune health of patients and existing comorbidities, affect both premalignant immunity and response to immunotherapy and, therefore, should be considered in managing patients with or without cancer. The Society for Immunotherapy of Cancer previously developed an overarching manuscript regarding the challenges and opportunities that exist in cancer immunotherapy, and this manuscript serves as an in-depth follow-up regarding the topics of premalignant immunity, immune interception, and immunoprevention, and the impact of the host on responding to immunotherapy. |
| format | Article |
| id | doaj-art-7600383c1bf046e5b6789dff36dbec59 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-7600383c1bf046e5b6789dff36dbec592025-08-20T03:12:46ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-03-0113310.1136/jitc-2024-010419SITC strategic vision: prevention, premalignant immunity, host and environmental factorsRaymond H Kim0Christian M Capitini1Mary L Disis2Claire Vanpouille-Box3Laszlo Radvanyi4Jennifer Wargo5Sasha E Stanton6Jennifer McQuade7Saman Maleki Vareki8Tullia C Bruno9Kristin G Anderson10Adnan Rajeh11Lauren K Hughes12Kelly J Baines13Megan M Y Hong14Phillip Awadalla1513 Department of Medicine, Familial Cancer Clinic, Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, Ontario, Canada5 Department of Pediatrics and Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA5 UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington, USA8 Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA7 Ontario Institute for Cancer Research and Department of Immunology, University of Toronto, Toronto, Ontario, Canada10 Departments of Surgical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA1 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA6 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA11 Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada3 Department of Immunology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA2 Department of Microbiology, Immunology and Cancer Biology, Department of Obstetrics and Gynecology, Beirne B. Carter Center for Immunology Research and the University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia, UK12 Department of Oncology, Western University, London, Ontario, Canada7 Ontario Institute for Cancer Research and Department of Immunology, University of Toronto, Toronto, Ontario, Canada11 Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada11 Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada7 Ontario Institute for Cancer Research and Department of Immunology, University of Toronto, Toronto, Ontario, CanadaCancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immunity and immune changes seen in lesions that develop into invasive cancer versus those that regress offers an exciting opportunity to leverage the immune system for immune prevention and immune interception of premalignancy. Understanding the immune environment of premalignant lesions and how chronic inflammation plays a central role in the evolution of premalignancy is essential for developing effective immunoprevention and immune interceptions. Factors such as host genomics and environmental factors that affect premalignant immunity and the outcome of advanced cancers are equally important in determining the response to immunotherapy. The broad use of antibiotics and factors such as obesity can disrupt a healthy gut microbiome and drive chronic inflammation that suppresses preventive immunity or the antitumor immune response required for successful immunotherapy in advanced cancers. Modifiable lifestyle factors such as diet, obesity, smoking, and stress should be considered in designing immune prevention and interception studies, as well as for patients who receive immunotherapy for advanced cancer treatment. Other factors, such as the overall immune health of patients and existing comorbidities, affect both premalignant immunity and response to immunotherapy and, therefore, should be considered in managing patients with or without cancer. The Society for Immunotherapy of Cancer previously developed an overarching manuscript regarding the challenges and opportunities that exist in cancer immunotherapy, and this manuscript serves as an in-depth follow-up regarding the topics of premalignant immunity, immune interception, and immunoprevention, and the impact of the host on responding to immunotherapy.https://jitc.bmj.com/content/13/3/e010419.full |
| spellingShingle | Raymond H Kim Christian M Capitini Mary L Disis Claire Vanpouille-Box Laszlo Radvanyi Jennifer Wargo Sasha E Stanton Jennifer McQuade Saman Maleki Vareki Tullia C Bruno Kristin G Anderson Adnan Rajeh Lauren K Hughes Kelly J Baines Megan M Y Hong Phillip Awadalla SITC strategic vision: prevention, premalignant immunity, host and environmental factors Journal for ImmunoTherapy of Cancer |
| title | SITC strategic vision: prevention, premalignant immunity, host and environmental factors |
| title_full | SITC strategic vision: prevention, premalignant immunity, host and environmental factors |
| title_fullStr | SITC strategic vision: prevention, premalignant immunity, host and environmental factors |
| title_full_unstemmed | SITC strategic vision: prevention, premalignant immunity, host and environmental factors |
| title_short | SITC strategic vision: prevention, premalignant immunity, host and environmental factors |
| title_sort | sitc strategic vision prevention premalignant immunity host and environmental factors |
| url | https://jitc.bmj.com/content/13/3/e010419.full |
| work_keys_str_mv | AT raymondhkim sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT christianmcapitini sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT maryldisis sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT clairevanpouillebox sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT laszloradvanyi sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT jenniferwargo sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT sashaestanton sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT jennifermcquade sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT samanmalekivareki sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT tulliacbruno sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT kristinganderson sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT adnanrajeh sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT laurenkhughes sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT kellyjbaines sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT meganmyhong sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors AT phillipawadalla sitcstrategicvisionpreventionpremalignantimmunityhostandenvironmentalfactors |